Bimmer E Claessen
Cardiology — Amsterdam University Medical Center, Netherlands
Bimmer E Claessen
LeadR Profile
Cardiology
Subspecialties: Surgery - Public Health - Thoracic And Cardiovascular Surgery
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2007 - 2026
Number : 369
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Technical and Target Lesion Failure in Calcified Coronary Lesions: Residual Risk Beyond Successful Lithotripsy. diabetes mellitus, stents, percutaneous coronary intervention, wounds and injuries, lithotripsy | JACC Adv | 2026 | 0 |
| Ticagrelor monotherapy versus dual antiplatelet therapy after primary percutaneous coronary intervention: one-year outcomes of the pilot STOP-IMH randomised trial. pilot projects, pilots, hemorrhage, ticagrelor, percutaneous coronary intervention, aspirin, cardiac surgical procedures, st elevation myocardial infarction, therapeutics | EuroIntervention | 2026 | 0 |
| Coronary angiography in cardiac arrest patients undergoing extracorporeal cardiopulmonary resuscitation. coronary angiography, resuscitation, cardiopulmonary resuscitation, hospital mortality, angiography, heart arrest, electrocardiography | Neth Heart J | 2026 | 0 |
| Short-term outcomes of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction; a randomized pilot study. pilot projects, pilots, safety, hemorrhage, myocardial infarction, ticagrelor, percutaneous coronary intervention, st elevation myocardial infarction, therapeutics, blood circulation | Am Heart J | 2026 | 0 |
| The impact of lipoprotein(a) on coronary atherosclerotic plaque phenotype in primary prevention. lipoproteins, c-reactive protein, cardiovascular diseases, phenotype, risk factors, primary prevention, artificial intelligence, lipoprotein(a), plaque, atherosclerotic | Eur J Prev Cardiol | 2026 | 0 |
Clinical Studies 13
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| An investigational trial to evaluate the effects of the drug XC001 delivered via a catheter in subjects with chronic angina caused by coronary artery disease (EXACT 2 Trial) 2024-514874-36-01 — genes, safety, coronary artery disease, pharmaceutical preparations, multiple chronic conditions, arteries, therapeutics, catheters | Phase 2 | Recruiting | 2026 |
| OCEAN(a) CCTA Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction Coronary Computed Tomography Angiography trial 2025-521117-88-00 — safety, tomography, lipoproteins, cardiovascular diseases, multiple chronic conditions, angiography, arteries, lipoprotein(a), computed tomography angiography | Phase 3 | Recruiting | 2026 |
| STOP IMH 2024-517783-37-00 — safety, myocardial infarction, incidence, ticagrelor, percutaneous coronary intervention, aspirin, st elevation myocardial infarction | Phase 4 | Recruiting | 2024 |
| Drug Eluting Balloon Treatment vs Guideline Directed Medical Therapy for the Treatment of Lipid Rich Plaques NCT07107971 — coronary artery disease, spectroscopy, near-infrared, paclitaxel, pharmaceutical preparations, tomography, heart, cardiovascular diseases, acute coronary syndrome, angiography, arteries, atherosclerosis, therapeutics, artificial intelligence, computed tomography angiography, catheters, lipids | N/A | Recruiting | 2025 |
| Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage NCT05986968 — safety, myocardial infarction, incidence, ticagrelor, percutaneous coronary intervention, aspirin, st elevation myocardial infarction, therapeutics | N/A | Active not recruiting | 2023 |
LeadR Networks
Main global connection map